Stason Pharmaceuticals, Inc.

Stason Pharmaceuticals' Mercaptopurine Tablets Recall Terminated: Supply Chain Implications

Stason Pharmaceuticals' voluntary Class III recall of 54,131 bottles of Mercaptopurine Tablets, USP 50 mg, due to failed dissolution specifications, has been terminated by the FDA. This event, impacting Quinn Pharmaceuticals' supply, underscores the need for robust quality oversight in contract manufacturing. Procurement and supply chain leaders must verify Stason's corrective actions to ensure future supply integrity for this critical chemotherapy drug.